Monitoring oral anticoagulant therapy – INR values for the Owren prothrombin time

• References

• 1 Quick AJ. The prothrombin time in hemophilia and in obstructive jaundice. J Biol Chem 1935; 109: 73-4.
• 2 Owren PA. Thrombotest. A new method for controlling anticoagulant therapy. Lancet 1959; 02: 754-8.
• 3 Loeliger EA, Van Den Besselaar AM, Lewis SM. Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thromb Haemost 1985; 53: 148-54.
• 4 WHO Expert Committee on Biological Standardization. Requirements for thromboplastins and plasmas used to control oral anticoagulant therapy. WHO Technical Report Series 1983; 33: 81-105.
• 5 WHO Expert Committee on Biological Standardization. Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy. WHO Report Technical Series. 1999 889..
• 6 Hirsh J, Dalen J, Anderson DR. et al.. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
• 7 Lindahl TL, Egberg N, Hillarp A. et al.. INR calibration of Owren type prothrombin time based on the relationship between PT% and INR utilizing normal plasma. Thromb Haemost. (in press).
• 8 Baele G, Fiers T, Leroux-Roels G. Comparison of a recombinant thromboplastin with Thrombotest for oral anticoagulant control. Haemostasis 1996; 26: 11-15.
• 9 Horsti J. Comparison of quick and owren prothrombin time with regard to the harmonisation of the International Normalised Ratio (INR) system. Clin Chem Lab Med 2002; 40: 399-403.
• 10 Kirkwood TB. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983; 49: 238-44.
• 11 Hillarp A, Egberg N, Nordin G. et al.. Local INR calibration of the Owren type prothrombin assay greatly improves the intra-and interlaboratory variation. A three-year follow-up from the Swedish national external quality assessment scheme. Thromb Haemost 2004; 91: 300-7.
• 12 Taborski U, Müller-Berghaus G. State-of-theart patient self-management for control of oral anticoagulation. Semin Thromb Hemost 1999; 25: 43-7.
• 13 Cromheecke ME, Levi M, Colly LP. et al.. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 2000; 356: 97-102.
• 14 White RH, McCurdy SA, von Marensdorff H. et al.. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study. Ann Intern Med 1989; 111: 730-7.
• 15 Fairweather RB, Ansell J, Van Den Besselaar AM. et al.. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy. Arch Pathol Lab Med 1998; 122: 768-81.
• 16 Poller L, Keown M, Chauhan N. et al.. European Concerted Action on Anticoagulation (ECAA): multicentre international sensitivity index calibration of two types of pointof-care prothrombin time monitor systems. Br J Haematol 2002; 116: 844-50.
• 17 Poller L, Keown M, Chauhan N. et al.. European Concerted Action on Anticoagulation. Correction of displayed international normalized ratio on two point-ofcare test whole-blood prothrombin time monitors (CoaguChek Mini and TAS PT-NC) by independent international sensitivity index calibration. Br J Haematol 2003; 122: 944-9.
• 18 Della VP, Crippa L, Garlando AM. et al.. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome. Haematologica 1999; 84: 1065-74.
• 19 Sanfelippo MJ, Sennet J, McMahon EJ. Falsely elevated INRs in warfarin-treated patients with the lupus anticoagulant. WMJ 2000; 99: 62-4 43.
• 20 Leech BF, Carter CJ. Falsely elevated INR results due to the sensitivity of a thromboplastin reagent to heparin. Am J Clin Pathol 1998; 109: 764-8.
• 21 Mattsson C, Menschiek-Lundin A, Wahlander K. et al.. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thromb Haemost 2001; 86: 611-5.
• 22 Walenga JM, Hoppensteadt D, Koza M. et al.. Laboratory assays for the evaluation of recombinant hirudin. Haemostasis 1991; 21 (Suppl. 01) 49-63.
• 23 Walenga JM, Fasanella AR, Iqbal O. et al.. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999; 25 (Suppl. 01) 61-6.
• 24 Jackson CM, Esnouf MP, Lindahl TL. A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy. Pathophysiol Haemost Thromb 2003; 33: 43-51.
• 25 Testa S, Morstabilini G, Fattorini A. et al.. Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system. Haematologica 2002; 87: 1265-73.
• 26 van Rijn JL, Schmidt NA, Rutten WP. Correction of instrument-and reagent-based differences in determination of the International Normalized Ratio (INR) for monitoring anticoagulant therapy. Clin Chem 1989; 35: 840-3.
• 27 Poggio M. The effect of instruments for prothrombin time testing on the international normalized ratio. Ric Clin Lab 1990; 20: 71-4.
• 28 Broze GJJ. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995; 6 (Suppl. 01) S7-S13.
• 29 Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
• 30 Sandset PM. Tissue factor pathway inhibitor (TFPI)—an update. Haemostasis 1996; 26 (Suppl. 04) 154-65.
• 31 Yang Y, He X, Li J, He S. [Effect of monoclonal antibody against human tissue factor pathway inhibitor on plasma coagulation time]. Hunan Yi Ke Da Xue Xue Bao 1997; 22: 297-300.
• 32 Broze Jr GJ. Protein Z-dependent regulation of coagulation. Thromb Haemost 2001; 86: 8-13.
• 33 Yin ZF, Huang ZF, Cui J. et al.. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci U.S.A 2002; 97: 6734-8.
• 34 Kemkes-Matthes B, Nees M, Kuhnel G. et al.. Protein Z influences the prothrombotic phenotype in Factor V Leiden patients. Thromb Res 2002; 106: 183-5.